New Drug, Pradaxa, May Prevent Second Stroke in Certain
MONDAY, Nov. 8 (HealthDay News) -- Among certain patients with a
history of stroke or mini-stroke, a new anticlotting medication
called Pradaxa (dabigatran) appears to be as effective as the
anticoagulant drug warfarin at preventing a second stroke, new
German research reveals.
Specifically, the new study suggests that Pradaxa can reduce the
risk of a second stroke as effectively as warfarin among those
facing an elevated risk for stroke or arterial blood clot (systemic
embolism) as a result of having atrial fibrillation, the most
common form of abnormal heart rhythm (or cardiac arrhythmia).
What's more, depending on the dosage used, Pradaxa appeared to
fare at least as well or better than warfarin in terms of limiting
the risk for bleeding -- a known warfarin side effect.
Pradaxa was recently approved by the U.S. Food and Drug
Administration -- at a dosage of 150 milligrams -- for the
prevention of first stroke among atrial fibrillation patients.
The current effort took a look at the drug in two twice-daily
dosages of either 110 mg or 150 mg among more than 3,600 atrial
fibrillation patients, all of whom had previously experienced a
stroke or a mini-stroke, also known as a transient ischemic
All of the patients had participated in the larger Randomized
Evaluation of Long-Term Anticoagulation Therapy study, which had
included more than 18,000 people, 80 percent of whom had no prior
history of stroke.
Last year, results of a prior analysis concerning this full
study group indicated that at the lower dosage, Pradaxa was as
effective at reducing stroke risk as warfarin, while the higher
dosage provided even better stroke protection than warfarin.
The new study, published in the Nov. 8 online edition of
The Lancet Neurology, was led by Dr. Hans-Christoph Diener from the department of neurology at University Hospital Essen in Essen, Germany.
Diener and his associates focused solely on a smaller subgroup
(taken from the larger trial) that had a history of stroke and,
therefore, a relatively higher risk for future stroke.
Among such particularly vulnerable patients, the study team
found that both dosages of Pradaxa were more or less as effective
as warfarin at controlling recurrent stroke risk.
In particular, the lower dosage of Pradaxa (110 mg) was also
linked to significant reduction in the rate of vascular death as
well as death from all causes, the researchers reported.
However, while major bleeding was also "significantly lower"
among the 110-mg Pradaxa group when compared with warfarin
patients, the higher dosage of 150 mg of Pradaxa twice daily
prompted a bleeding risk that was as high as that found among
Diener and his colleagues remain unclear as to exactly why the
lower dose of Pradaxa prompts a lower rate of bleeding than
warfarin, although they speculate that at that dose the drug may
not cross the central nervous system's blood-brain barrier,
resulting in an improved safety profile.
"In choosing the dose of dabigatran, physicians need to trade off the benefits of stroke prevention against the risk of hemorrhage," the study authors advised in a news release from the publisher.
"In general, strokes are more severe than major hemorrhages and have more significant long-term consequences," Diener's team added. "The dose of 150-mg dabigatran twice daily could be preferred to 110-mg twice daily because it significantly reduces the risk of ischemic stroke without increasing the risk of hemorrhagic stroke."
Meanwhile, the British research team of Dr. Gregory Y.H. Lip and
Deirdre A. Lane, both from the University of Birmingham Centre for
Cardiovascular Sciences, offered commentary on the new findings in
the same issue of the journal. They wrote: "Because of the
necessary trade-off between stroke prevention and bleeding with
both doses of dabigatran, consultation with patients regarding
their preferences for treatment dose will be even more important to
ascertain their threshold for stroke prevention over increased
bleeding risk or vice versa."
The study was funded by Boehringer-Ingelheim, which makes
For more on stroke risk, visit the
American Heart Association.
Copyright © 2010
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.